Key regions: Brazil, India, Australia, United States, United Kingdom
The Antiviral Drugs market in Benin has been steadily growing in recent years.
Customer preferences: As with other countries in the region, the demand for antiviral drugs in Benin is largely driven by the prevalence of infectious diseases such as HIV/AIDS, hepatitis B, and malaria. Customers in Benin are also increasingly seeking out antiviral drugs as a preventative measure, particularly for diseases such as COVID-19.
Trends in the market: One of the major trends in the Antiviral Drugs market in Benin is the increasing availability of generic drugs. This has been driven by the government's efforts to make healthcare more affordable and accessible to the wider population. As a result, many customers are now able to access antiviral drugs at more affordable prices than before.Another trend in the market is the growing popularity of natural remedies and traditional medicine. While this trend is not unique to Benin, it is particularly pronounced in the country due to the widespread belief in the healing power of natural remedies. As a result, many customers are turning to traditional medicine in place of antiviral drugs.
Local special circumstances: One of the key factors shaping the Antiviral Drugs market in Benin is the country's healthcare infrastructure. While the government has made efforts to improve healthcare access and affordability, there are still significant gaps in the system. This has led to a situation where many customers are unable to access the care they need, particularly in rural areas.
Underlying macroeconomic factors: The Antiviral Drugs market in Benin is also influenced by broader macroeconomic factors such as the country's GDP growth rate and foreign investment. While the economy has been growing in recent years, it remains heavily reliant on agriculture and is vulnerable to external shocks such as changes in global commodity prices. This has led to a situation where many customers are unable to afford the cost of healthcare, including antiviral drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
